Longitudinal evaluation of liver stiffness and outcomes in patients with chronic hepatitis C before and after short- and long-term IFN-free antiviral treatment
- 21 November 2019
- journal article
- research article
- Published by Taylor & Francis Ltd in Current Medical Research and Opinion
- Vol. 36 (2), 245-249
- https://doi.org/10.1080/03007995.2019.1691517
Abstract
BACKGROUND. New direct-acting antiviral drugs can eradicate hepatitis C virus (HCV) infection in over 90% of patients and can even reduce the risk of complications in advanced fibrosis/cirrhosis. The aims of this study were to evaluate 1) changes in fibrosis during and after antiviral treatment and 2) incidence of hepatocarcinoma and mortality in various fibrosis stages. METHODS. This is a longitudinal monocentric prospective study. Blood and instrumental examinations were evaluated at baseline, at the end of therapy, and 1 and 2 years following treatment. RESULTS. Two hundred and ninety-six patients with chronic HCV were evaluated, of whom 115 were experienced, 181 were treatment-naïve, and 2 had previous hepatocellular carcinoma (HCC) and were therefore excluded from the study. At baseline, stiffness values were 13.46 ± 9.97 kPa. Out of the 294 HCV patients enrolled, 100 had lymphoproliferative disorders and were evaluated separately. This group of patients showed stiffness values pertaining to the F0-F2 group (mean stiffness values were 6.07 ± 1.68 kPa). All other patients showed stiffness values pertaining to the F3-F4 group (mean stiffness values were 17.93 ± 10.23). No statistically significant difference was found between stiffness at baseline compared to the end of treatment (EOT), while significant differences were found between the baseline, 1 year (p = 0.05), and 2-year follow-ups (p < 0.01). Significant differences were found between baseline and EOT, as well as 1 and 2 years after the end of treatment (p < 0.001) in the F3-F4 group. Four out of 140 patients with baseline cirrhosis developed HCC during the post-treatment follow-up, 1 of whom died. CONCLUSIONS. Non-invasive methods provide important prognostic information, particularly concerning the observed regression of fibrosis and could be extremely useful for monitoring patients with long life expectancies after direct-acting antiviral treatment.Keywords
This publication has 29 references indexed in Scilit:
- Longitudinal Liver Stiffness Assessment in Patients with Chronic Hepatitis C Undergoing Antiviral TherapyPLOS ONE, 2012
- Safety and efficacy of rituximab in patients with hepatitis C virus–related mixed cryoglobulinemia and severe liver diseaseBlood, 2010
- Changes in liver stiffness in patients with chronic hepatitis C with and without HIV co-infection treated with pegylated interferon plus ribavirinJournal of Antimicrobial Chemotherapy, 2010
- Liver stiffness decrease after effective antiviral therapy in patients with chronic hepatitis C: Longitudinal study using FibroScanJournal of Gastroenterology and Hepatology, 2010
- Reduction of liver stiffness by interferon treatment in the patients with chronic hepatitis CHepatology Research, 2010
- Transient elastography for the assessment of liver fibrosis in patients with chronic viral hepatitis: The missing tool?Digestive and Liver Disease, 2009
- The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirinAntiviral Research, 2009
- A model to predict survival in patients with end-stage liver diseaseJournal of Hepatology, 2001
- T(14;18) translocation in chronic hepatitis C virus infectionJournal of Hepatology, 2000
- Transection of the oesophagus for bleeding oesophageal varicesBritish Journal of Surgery, 1973